AFM
BNTC icon

Anson Funds Management’s Benitec Biopharma BNTC Stock Holding History

Anson Funds Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,710
Closed -$137K – 120
2025
Q2 		$137K Buy
+11,710
New +$164K 0.02% 99

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Anson Funds Management's BNTC Position: Q3 2025 in Review

Anson Funds Management sold out of Benitec Biopharma (BNTC) in Q3 2025, closing a stake of 11,710 shares — an estimated $137K sold.

Anson Funds Management first reported a position in BNTC in Q2 2025 and held it in 1 quarter. The position peaked at $137K in Q2 2025. 56 funds tracked by Wall St. Rank hold BNTC as of Q3 2025.

  • Anson Funds Management reported no remaining Benitec Biopharma position as of Q3 2025 after selling out during the quarter.
  • Anson Funds Management sold 11,710 Benitec Biopharma shares in Q3 2025, an estimated $137K.
  • Anson Funds Management first reported a position in Benitec Biopharma in Q2 2025 and held it in 1 quarter.
  • Anson Funds Management's Benitec Biopharma position peaked at $137K in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2025.

Based on Anson Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.